Conference Presentation, Panel
Opioid Addiction: A Crisis Fueled by Stigma
Milken InstituteRobert Redfield, Sarah Carlin-Smith, Dr. Kelly Clark, Gary Mendel, Dr. Andrei Ostrovsky, Jerome Adams, Ronnie Solomon, Michael Golinkoff
- A five-point strategy including national standards, payment reform, professional training, and quality measurement is under development, with stigma identified as the sole unaddressed element; McKinsey is conducting a three-to-four-month pro bono study to adapt social change strategies from HIV/AIDS, marriage equality, and teen smoking campaigns for stigma reduction.
- A central coordinating organization similar to Tobacco-Free Kids or Freedom to Marry is proposed to unify stigma reduction efforts, while a five-month collaborative plan targets six systems: employers, healthcare, criminal justice, media, government, and local communities.
- Education strategies differ by audience, focusing on language and content for middle schoolers and humanizing stories for high schoolers and adults; a prototype toolkit for the 1,000 largest companies aims to reach 30 million employees to alter perceptions at zero cost.
- Policy actions include eliminating the X-waiver to remove bureaucratic barriers, expanding Medicaid to improve outcomes without new statutes, and educating judges on clinical evidence, alongside a need to shift perspectives from judgment to viewing substance use disorder as a chronic disease.
- Infrastructure gaps include 60% of facilities not utilizing medication and less than 40% offering one of the three NIDA-developed medications, with only 2% offering all three; the current system requires building a totality of care infrastructure with correct staffing and modalities to address provider availability and reimbursement disparities.
- Funding disparities highlight NIDA's $1.4 billion budget against cancer's $7 billion and heart disease's $4 billion despite substance use disorders affecting twice as many people; a HEAL initiative funding four states (Massachusetts, Ohio, New York, Kentucky) aims to reduce mortality by 50% within 1.5 years, while recovery research requires acceleration.
- Rhode Island data indicated that 2/3 of opioid users leaving incarceration chose methadone, 1/3 buprenorphine, and 1% extended-release naltrexone, leading to a dramatic overdose rate decrease over six months; however, Kentucky and other partners developed a "Kentuckiana Healthcare Collaborative" toolkit to address workplace issues.
- Risks include the potential diversion of opioid settlement funds to unrelated state issues, evidenced by tobacco settlement funds being used for potholes, and the current underfunding of the Bureau of Prisons contributing to recidivism and post-discharge deaths; over 2,500 lawsuits against hospitals and drug companies are creating a long-term distribution process.
- Financial and legal barriers include insufficient physician reimbursement rates compared to surgical procedures, the requirement for Medicaid beneficiaries to lose coverage and face reapplication hurdles upon entering prison, and the perception that privacy protections under 42 CFR institutionalize stigma by restricting law enforcement interaction to subpoena.
- The National Academies of Medicine Opiol Collaborative is expected to release two reports within the next six months outlining the current and ideal states of the prevention, treatment, and recovery system, while health plans and brokers need a framework to eliminate stigma in reimbursement decisions.
- Media narratives highlighting criminal justice benefits of recovery may worsen stigma, despite the goal of reducing crime; removing the X-waiver is characterized as a necessary but small policy step, whereas comprehensive plans require broad social change strategies similar to those used in other major public health campaigns.